Michael Oropallo

Michael Oropallo

Company: Merck & Co

Job title: Principal Scientist


Development of in vitro Assays for Off-Target ADC Hematotoxicity 1:45 pm

Summarizing potential mechanisms driving off-target ADC hematotoxicity  Developing in vitro approaches to differentiate ADCs based on toxicity to neutrophils and megakaryocytes Investigating mechanisms of off-target hematotoxicity including the role of FC receptor mediated uptakeRead more

day: Conference Day 1

Panel – Bench to Bedside & Back – Assessing the Benefits of a Reverse Translational Approach When Minimizing ADC Toxicities 12:00 pm

Viewing the ways toxicities present themselves clinically to consider what can be done preclinically to mitigate these effects Transferring from human studies to animal studies to obtain a deeper understanding of how different ADCs are distributed across healthy tissues Understanding potential biomarkers for predicting toxicities which present in humans and being able to connect this…Read more

day: Conference Day 2

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.